AB Science announces the implementation of a new strategy and the completion, in support of this, of a capital increase through the issue of new shares and a private placement for an amount of 15 million euros (including issue premium).

The company intends to focus its development strategy on amyotrophic lateral sclerosis with its masitinib platform, on the second microtubule platform and to seek partnerships for non-rare disease indications for masitinib.

The capital increase gives rise to the issue of 2,608,686 shares at a price of 5.75 euros, with warrants attached, the exercise of which would bring the total amount of the operation to around 26.3 million euros (i.e. a total of 3,913,029 new shares).

Copyright (c) 2023 CercleFinance.com. All rights reserved.